Parkinson’s disease biomarkers based on α-synuclein

Muneera Fayyad, Safa Salim, Nour Majbour, Daniel Erskine, Erik Stoops, Brit Mollenhauer, Omar Ali El-Agnaf

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease and is estimated to affect approximately 1–4% of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease-modifying therapies for Parkinson’s disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson’s disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non-invasive means is a pressing issue in the field. Since the discovery of α-synuclein (α-syn) as a protein linked to a familial form of Parkinson’s disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson’s disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson’s disease biomarker discovery with a focus on α-synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α-synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions. (Figure presented.). “This article is part of the Special Issue Synuclein.”.

Original languageEnglish
Pages (from-to)626-636
Number of pages11
JournalJournal of Neurochemistry
Volume150
Issue number5
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Synucleins
Biomarkers
Parkinson Disease
Proteins
Neurodegenerative Diseases
Alzheimer Disease
Clinical Trials
Assays
Therapeutics
Tissue

Keywords

  • biomarkers
  • Parkinson's disease
  • α-synuclein

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Parkinson’s disease biomarkers based on α-synuclein. / Fayyad, Muneera; Salim, Safa; Majbour, Nour; Erskine, Daniel; Stoops, Erik; Mollenhauer, Brit; Ali El-Agnaf, Omar.

In: Journal of Neurochemistry, Vol. 150, No. 5, 01.01.2019, p. 626-636.

Research output: Contribution to journalReview article

Fayyad, M, Salim, S, Majbour, N, Erskine, D, Stoops, E, Mollenhauer, B & Ali El-Agnaf, O 2019, 'Parkinson’s disease biomarkers based on α-synuclein', Journal of Neurochemistry, vol. 150, no. 5, pp. 626-636. https://doi.org/10.1111/jnc.14809
Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B et al. Parkinson’s disease biomarkers based on α-synuclein. Journal of Neurochemistry. 2019 Jan 1;150(5):626-636. https://doi.org/10.1111/jnc.14809
Fayyad, Muneera ; Salim, Safa ; Majbour, Nour ; Erskine, Daniel ; Stoops, Erik ; Mollenhauer, Brit ; Ali El-Agnaf, Omar. / Parkinson’s disease biomarkers based on α-synuclein. In: Journal of Neurochemistry. 2019 ; Vol. 150, No. 5. pp. 626-636.
@article{2dd3a903575b45cfa957fedc08df6e7a,
title = "Parkinson’s disease biomarkers based on α-synuclein",
abstract = "Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease and is estimated to affect approximately 1–4{\%} of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease-modifying therapies for Parkinson’s disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson’s disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non-invasive means is a pressing issue in the field. Since the discovery of α-synuclein (α-syn) as a protein linked to a familial form of Parkinson’s disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson’s disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson’s disease biomarker discovery with a focus on α-synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α-synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions. (Figure presented.). “This article is part of the Special Issue Synuclein.”.",
keywords = "biomarkers, Parkinson's disease, α-synuclein",
author = "Muneera Fayyad and Safa Salim and Nour Majbour and Daniel Erskine and Erik Stoops and Brit Mollenhauer and {Ali El-Agnaf}, Omar",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jnc.14809",
language = "English",
volume = "150",
pages = "626--636",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Parkinson’s disease biomarkers based on α-synuclein

AU - Fayyad, Muneera

AU - Salim, Safa

AU - Majbour, Nour

AU - Erskine, Daniel

AU - Stoops, Erik

AU - Mollenhauer, Brit

AU - Ali El-Agnaf, Omar

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease and is estimated to affect approximately 1–4% of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease-modifying therapies for Parkinson’s disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson’s disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non-invasive means is a pressing issue in the field. Since the discovery of α-synuclein (α-syn) as a protein linked to a familial form of Parkinson’s disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson’s disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson’s disease biomarker discovery with a focus on α-synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α-synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions. (Figure presented.). “This article is part of the Special Issue Synuclein.”.

AB - Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease and is estimated to affect approximately 1–4% of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease-modifying therapies for Parkinson’s disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson’s disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non-invasive means is a pressing issue in the field. Since the discovery of α-synuclein (α-syn) as a protein linked to a familial form of Parkinson’s disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson’s disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson’s disease biomarker discovery with a focus on α-synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α-synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions. (Figure presented.). “This article is part of the Special Issue Synuclein.”.

KW - biomarkers

KW - Parkinson's disease

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=85070922187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070922187&partnerID=8YFLogxK

U2 - 10.1111/jnc.14809

DO - 10.1111/jnc.14809

M3 - Review article

C2 - 31265130

AN - SCOPUS:85070922187

VL - 150

SP - 626

EP - 636

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 5

ER -